Valturna

Valturna is a brand name of aliskiren/valsartan, approved by the FDA in the following formulation(s):

VALTURNA (aliskiren hemifumarate; valsartan - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: September 16, 2009
  
  Strength(s): EQ 150MG BASE;160MG, EQ 300MG BASE;320MG ^[RLD]

Has a generic version of Valturna been approved?

No. There is currently no therapeutically equivalent version of Valturna available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Valturna. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Acyl compounds
  Patent 5,399,578
  Issued: March 21, 1995
  Inventor(s): Buhlmayer; Peter & Ostermayer; Franz & Schmidlin; Tibur
  Assignee(s): Ciba-Geigy Corp
  Compounds of the formula ##STR1## in which R.sub.1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X.sub.1 is CO, SO.sub.2, or --O--C(.dbd.O)-- with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X.sub.2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R.sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O).sub.m --R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO.sub.n H.sub.2 where n is 2 or 3; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl, 5-tetrazolyl, SO.sub.3 H, PO.sub.2 H.sub.2, PO.sub.3 H.sub.2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.
  
  Patent expiration dates:
  
  
  • March 21, 2012
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides
  Patent 5,559,111
  Issued: September 24, 1996
  Inventor(s): G oschke; Richard & Maibaum; J urgen K. & Schilling; Walter & Stutz; Stefan & Rigollier; Pascal & Yamaguchi; Yasuchika & Cohen; Nissim C. & Herold; Peter
  Assignee(s): Ciba-Geigy Corporation
  .delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1## and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive medicinal active ingredients.
  
  Patent expiration dates:
  
  
  • July 21, 2018
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 5, 2012 - NEW CHEMICAL ENTITY
  
  
  • September 16, 2012 - NEW COMBINATION
  
  

See also...

• Valturna Consumer Information (Drugs.com)
• Valturna Consumer Information (Wolters Kluwer)
• Valturna Consumer Information (Cerner Multum)
• Valturna Advanced Consumer Information (Micromedex)
• Aliskiren/Valsartan Consumer Information (Wolters Kluwer)
• Aliskiren and valsartan Consumer Information (Cerner Multum)
• Aliskiren and valsartan Advanced Consumer Information (Micromedex)

Rougier Vap

Rougier Vap may be available in the countries listed below.

Ingredient matches for Rougier Vap

Chlorhexidine

Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Rougier Vap in the following countries:

• Canada

International Drug Name Search

Amlopp

Amlopp may be available in the countries listed below.

Ingredient matches for Amlopp

Amlodipine

Amlodipine maleate (a derivative of Amlodipine) is reported as an ingredient of Amlopp in the following countries:

• Czech Republic

International Drug Name Search

Zopiklon Mylan

Zopiklon Mylan may be available in the countries listed below.

Ingredient matches for Zopiklon Mylan

Eszopiclone

Zopiclone is reported as an ingredient of Zopiklon Mylan in the following countries:

• Sweden

International Drug Name Search

Korandil

Korandil may be available in the countries listed below.

Ingredient matches for Korandil

Enalapril

Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Korandil in the following countries:

• Bahrain


• Cyprus


• Malta


• Singapore

International Drug Name Search

Sleepil

Sleepil may be available in the countries listed below.

Ingredient matches for Sleepil

Eszopiclone

Eszopiclone is reported as an ingredient of Sleepil in the following countries:

• Bangladesh

International Drug Name Search

Findol

Findol may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Findol

Glucosamine

Glucosamine sulfate (a derivative of Glucosamine) is reported as an ingredient of Findol in the following countries:

• Argentina

Ketoprofen

Ketoprofen is reported as an ingredient of Findol in the following countries:

• Italy

International Drug Name Search

Apo-Bactotrim

Apo-Bactotrim may be available in the countries listed below.

Ingredient matches for Apo-Bactotrim

Sulfamethoxazole

Sulfamethoxazole is reported as an ingredient of Apo-Bactotrim in the following countries:

• Peru

Trimethoprim

Trimethoprim is reported as an ingredient of Apo-Bactotrim in the following countries:

• Peru

International Drug Name Search

Diclon rapid

Diclon rapid may be available in the countries listed below.

Ingredient matches for Diclon rapid

Diclofenac

Diclofenac potassium salt (a derivative of Diclofenac) is reported as an ingredient of Diclon rapid in the following countries:

• Denmark

International Drug Name Search

Spasmol

Spasmol may be available in the countries listed below.

Ingredient matches for Spasmol

Drotaverine

Drotaverine is reported as an ingredient of Spasmol in the following countries:

• Russian Federation

International Drug Name Search

Carboplamin

Carboplamin may be available in the countries listed below.

Ingredient matches for Carboplamin

Carboplatin

Carboplatin is reported as an ingredient of Carboplamin in the following countries:

• Greece

International Drug Name Search

PMS-Lindane

PMS-Lindane may be available in the countries listed below.

Ingredient matches for PMS-Lindane

Lindane

Lindane is reported as an ingredient of PMS-Lindane in the following countries:

• Canada


• Hong Kong

International Drug Name Search

Ciclosporina Cantabria

Ciclosporina Cantabria may be available in the countries listed below.

Ingredient matches for Ciclosporina Cantabria

Ciclosporin

Ciclosporin is reported as an ingredient of Ciclosporina Cantabria in the following countries:

• Spain

International Drug Name Search